Glucose utilization and secretion of insulin and growth hormone after intravenous administration of glucose were measured during the evolution of myocardial infarctions. Tw9 patterns of responses were found. Patients who developed myocardial infarction with either no prior cardiovascular disease or stable coronary artery disease had depressed glucose utilization for the first 48 hours and exhibited a hyperinsulinemic response to glucose during the sixth to fourteenth day; and, about 50% of them, had an increase in the secretion of growth hormone during the initial 4 days of the infarction. Patients who had had progressively increasing angina in the 7 to 14 days preceding infarction showed a different pattern. No initial depression of glucose utilization was found. Their hyperinsulinemic response occurred within the first 96 hours of the occlusion. Growth hormone secretion was increased in 83% of the patients during the first 96 hours. The data suggest the possibility that the exaggerated insulin secretion may be associated with myocardial repair processes while the changes in growth hormone secretion may be related to the acute stress or necrosis of the infarction. Additional Indexing Words: Myocardial repair U T HE IMPORTANCE of metabolic alterations during acute myocardial infarctions has received increasing attention in the last several years. Hyperglycemia and abnormalities in glucose tolerance have been reported in as many as 35 to 85% of patients with acute cardiac infarctions.14 The relationship between the abnormality in carbohydrate tolerance and the coronary artery disease has been the subject of numerous investiga- 3tions. 3 Oliver and co-workers6 have measured serum free fatty acids in 200 patients during the first 48 hours after acute myocardial infarction and have proposed a relationship between high levels and an increased incidence of arrhythmias and death. Increases in secretion of both adrenal cortical and the adrenal medullary hormones have been observed during acute infarctions.7-9
Studies of myocardial infarctions in experimental animals have suggested that anabolic hormones facilitate healing. Gudbiarnason and associates'0 demonstrated that insulin, growth hormone, and anabolic steroids all increased glycine-2 14 C incorporation into the connective tissue of healing infarcts in dogs.
The present study was directed toward defining the nature of the acute metabolic responses to myocardial infarctions in humans and the possible relationship of these changes to the clinical course of the patients. This particular communication describes serial changes in glucose utilization and insulin and growth hormone secretion following intravenously administered glucose during the evolution of acute myocardial infarctions.
Methods
The patients were carefully monitored for arrhythmias and changes in cardiac status. Patients with known diabetes mellitus were excluded from the study. Most of the patients studied were relatively stable and did not have significant hypotension or ventricular arrhythmias after the initial few hours of the acute infarction. Because of the nature of the illness, many of them received a variety of drugs including morphine, lidocaine, heparin, and warfarin. Since drugs, such as sympathetic amines, a or ,3 adrenergic blockers, and various thiazide derivatives, are known to influence insulin secretion, the patients in this study were carefully screened to eliminate those taking such drugs. Many of the patients had an indwelling venous catheter in the superior vena cava for the first 4 or 5 days, which was kept open by a slow drip of 5% glucose in water.
Glucose tolerance tests were performed by administering intravenously 25 g of glucose (50 ml of 50% glucose in water) over a 1 to 2-min period. Samples were drawn for determinations of glucose, insulin, and growth hormone before the glucose was administered and at 5-min intervals for 60 min afterward. A 2Y2-min sample was also routinely collected. Where a slow glucose infusion was keeping an indwelling catheter open, the infusion fluid was changed to normal saline 30 min before the 25 g of glucose was
given.
Blood glucose was measured on barium hydroxide-zinc sulfate filtrates by a glucose oxidase method." The regression coefficient (b) of the logarithm of blood glucose was calculated from the linear segment of the curve using the method of least squares and converted to the fractional glucose decay constant (K) by the formula K = 230.3b. This value expresses the rate of fall of the blood glucose in per cent per minute and can be considered as an estimate of glucose utilization. '2 Plasma insulin and growth hormone were measured by a double antibody immunoassay method using 1251-labeled pork insulin and hu-man growth hormone as tracers and human insulin and growth hormone standards.'3
The acute infarction was arbitrarily divided into three periods. Period 1 was defined as the first 96 hr after the occlusion and represented the time of the acute stress. Period 2 was from day 6 to day 14 after the occlusion and corresponds to the time that proliferation of blood vessels and fibroblasts is occurring in the infarcted area. Period 3 was after day 18 and corresponds to a later healing stage of the infarct. Where possible, the response to intravenously administered glucose was studied in each of these periods in each patient.
Total insulin and growth hormone secretion following the intravenous glucose was estimated by calculating the areas under the plasma curves as described previously.'4 For insulin this calculation was done for the time intervals 0 to 20 min and 0 to 60 min. For growth hormone this was done for the time interval 0 to 60 min.
Results
The reproducibility of the glucose disposal constant (K) and insulin and growth hormone secretion following intravenous glucose was examined in five normal individuals (table 1) . Duplicate studies were performed 2 to 35 days apart. The glucose disposal constants varied only slightly and were not significantly different in the two studies. The duplicate 20-min insulin secretion varied by no more than 15.9%, and the 60-min secretion by 6% or less. No significant difference was noted in secretion of growth hormone. Table 2 summarizes the clinical data and the glucose disposal constants in the patients in the present study. As the study progressed, it became obvious that the patients could be subdivided into two major clinical groups. In group A were those patients who developed acute coronary occlusion with either no known prior cardiovascular disease or a stable coronary artery disease syndrome with well-controlled mild angina. In group B were those patients who had severe or progressive angina for several days to 2 weeks prior to their admission for the acute occlusion. In group A, the patients were further subdivided as to whether the initial glucose tolerance test was performed within the first 48 hours of the occlusion or later. K1, K2, and K3 represent the glucose disposal constants measured during the three different periods. The day each study was performed is also listed. In group A, the glucose disposal constant was depressed in all the patients during the first 48 hours. The value increased by the second study and was little changed between the second and third study. In those patients in whom the initial study was done after 48 hours, no difference in glucose disposal was observed between it and subsequent studies. In group B there was either no change in K value from study 1 to 2 or, as in A.N. and C.H., a significant decrease.
Glucose Disposal Constants

Insulin Secretion
Insulin secretion, as estimated by calculating the area under the plasma insulin curve for 1 hour following the glucose load, differed considerably during the three periods of the infarction. These data are shown in table 3.
In the group A patients the insulin secre-Circulation, Volume XXXIX, Feb-uary 1969 tion was greater (P < 0.01) in period 2 (mean + SEM 4,986 + 490 uU-min/ml [micro-unit-min/ml] ) than in period 1 (mean + SEM 3,055 ± 472 ,U-min/ml) or period 3(mean + SEM 3,415 + 564 ,uU-min/ml). There was no significant difference between insulin secretion in periods 1 and 3. Group B patients had their greatest insulin secretion in period 1 (mean+± SEM 7,417 + 1,584 ,U-min/ml).
Since insulin secretion varied greatly from patient to patient, it seemed more reasonable to use each patient as his own control and express the data in such a way that they could be meaningfully combined. Therefore, the insulin secretion in period 2 for each patient was arbitrarily assigned a value of 1, and the insulin secretion in periods 1 and 3 was expressed as the percentage of period 2 secretion. Because the 60-min insulin secretion is dependent on the sustained blood glucose level and this was decidedly different in period 1, insulin secretion was expressed both as initial (0 to 20 min) and total secretion (0 to 60 min). Table 4 summarizes these data. This method of expression shows even more clearly that in group A patients, period 2 is associated with exaggerated insulin secretion whereas in group B, the increased secretion occurs in period 1. While the total insulin secretion in group A patients was approximately the same in periods 1 and 3, the initial insulin secretion was less in period 1 than in period 3. Figures 1 and 2 illustrate the glucose disposal, and plasma insulin and plasma growth hormone response to glucose in the three periods in patients who are representative of group A and group B patients, respectively. In figure 1 (group A patient, C. W.) glucose utilization was markedly impaired in period 1 but returned toward normal in periods 2 and 3. The plasma insulin response to glucose in the initial study showed a blunting of the immediate response, but persistently Figures 1 and 2 illustrate the changes in plasma growth hormone that accompany the changes in glucose disposal and insulin secretion. In each of the studies shown, the fasting plasma levels of growth hormone were normal, but a striking rise in growth hormone levels followed glucose administration. This release of the growth hormone by glucose was less in period 2 and returned to that seen in normals by period 3. Table 5 summarizes the growth hormone secretion in all the patients in this study. Seven of the 12 patients in group A had increased growth hormone secretion after administration of glucose in period 1 while five of six showed this in group B. In most instances the growth hormone secretion lessened in periods 2 and 3. In patient M. G. the high growth hormone secretion in period 3 followed a renal infarction.
Correlation of Metabolic Response to Clinical Course
Most of the patients studied in this series have been followed for 6 to 12 months, and it is not possible to make any valid correlations between the changes measured and the course of the patients. It is surprising, however, that of the three patients who have subsequently died suddenly (from 10 to 60 days after the initial occlusion) all had very high growth hormone secretion in the initial study (M.S., R.C., and B. R.).
Discussion
The present study shows that the pattern of metabolic changes following an acute myo- cardial infarction is dependent on whether the infarction occurs as a solitary event or is preceded by a recent episode of preinfarction injury. In the case of a sudden coronary occlusion (group A), intravenous glucose tolerance is depressed for 48 hr and then increases toward normal. Insulin secretion is essentially the same in the first few days of the occlusion as it is in the late healing stage of the infarction. There is, however, a striking hyperinsulinemic response to glucose in period 2 (days 6 to 14 after the acute infarction). Slightly over 50% of the patients had increased growth hormone secretion in response to glucose in the initial 96 hr after the cardiac infarction. In contrast, the patients who had recent preinfarction injury followed by an acute coronary -occlusion (group B) did not have initial changes in glucose utilization and had the hyperinsulinemic response in the initial Circulation, Volume XXXIX, February 1969 20 minutes and the entire 60 minutes. studies in period 1. Increased growth hormone secretion was present in the initial study in five of the six patients.
Interpretation of the significance of changes in glucose utilization and insulin and growth hormone secretion during the evolution of an illness such as a myocardial infarction is extremely difficult. The initial few days of the illness are characterized by both an acute response to stress and changes in circulatory dynamics.
The influence that those factors might have on glucose utilization and insulin and growth hormone secretion are many. Several studies have shown that urinary catecholamine excretion is significantly elevated during an acute myocardial infarction.8 9, 15 This elevation may be due to increased excretion of epinephrine, norepinephrine, or both and in most instances persists for the initial 24 to 72 hours of the acute infarction. cose and intravenous tolbutamide in individinfarction 11 days prior to this study. uals receiving dexamethasone, 8 mg/day for 3 days. Since the glucocorticoid activity of 8 mg of dexamethasone is probably equivf the patients in the present study alent to, or greater than, that of 250 mg of asurements taken of urinary catecholcortisone, it is not possible to establish from at some time during the study and their data the extent of the change in plasma f the 11 patients whose urinary cate-insulin response that might result from the ines were measured during the first degree of adrenocortical activity observed showed some elevations.9 Infusions of during the early phase of a myocardial inrine and norepinephrine at pharma-farction. Even though changes in insulin il doses have markedly inhibited in-responsiveness might be caused by the incretion in response to glucose and other creased plasma corticoids of the patient with genic stimuli in normal volunteers.16 17 an infarction, it is unlikely that the changes minutes of the cessation of an epinephin insulin responsiveness noted in period 2 usion, there is a rebound release of in-of the group A patients were due to in-Vhether the physiological amount of creased plasma corticoids because the hyperlamines released in response to an insulinemic response occurred 4 to 10 days nyocardial infarction is sufficient to after the plasma corticoid levels presumably insulin release is difficult to determine, returned to normal. The elevated plasma re is certainly little likelihood that any corticoids could, however, be responsible for lamine effects could consistently occur the early impairment of glucose tolerance the third or fourth day of a myocardial noted in the group A patients. Dn. Thus, it is possible that the impair-Changes in circulatory dynamics have F glucose utilization noted during the been shown to alter glucose metabolism hours after infarction in group A without significantly changing plasma insucould be due to epinephrine stim-lin levels. 19 These effects are probably best Circulation, Volume XXXIX, February 1969 explained by the release of catecholamines.
The patients in the present study were selected because of their relatively uncomplicated illnesses and, therefore, changes in circulatory dynamics played no role in the observed metabolic changes. Table 2 lists the complications which did occur. Though it was possible to exclude the influence of many drugs that are known to alter insulin secretion (pressor agents, adrenergic blockers, and thiazide derivatives) by limiting the study to patients with relatively uncomplicated myocardial infarctions, it was not possible to exclude many other drugs that might have effects. Virtually all of the patients received morphine or meperidine (Demerol) for the first 12 to 36 hr after infarction. About half of the patients received quinidine or lidocaine during the initial 3 or 4 days, but results of studies on them did not differ significantly from those on patients who did not receive those drugs. Almost all of the patients received heparin as an anticoagulant for the first few days and about half of the patients were taking warfarin during the second and third period of study. Bishydroxycoumarin (Dicumarol) in 5 x 104 M has been reported to increase insulin release from rabbit pancreatic tissue in vitro.20 There are no human studies to determine if this effect occurs in vivo with ordinary therapeutic doses. Since the results in patients taking warfarin were the same as in those not taking it, and since patients taking the drug continued it throughout the second and third study, it seem unlikely that the insulin changes observed in our patients could have resulted from the warfarin therapy.
The pattern of growth hormone secretion in the patients with acute cardiac infarctions is as difficult to interpret as is the pattern of insulin secretion. Numerous studies have emphasized the lability of the plasma growth hormone level.21 The plasma level of growth hormone rises abruptly from that in the resting state with such things as emotional upset,22 muscular exercise,21 arterial puncture,23 surgical stress,2' and administration Circulation, Volume XXXIX, February 1969 of bacterial endotoxin.'2 In general, oral or intravenous administration of glucose will decrease an elevated concentration of plasma growth hormone to resting levels in a normal individual.2' However, the elevated level of plasma growth hormone observed during major surgery or after endotoxin administration is not suppressible by glucose.21 24 Patients with acute myocardial infarctions might have been expected to have markedly elevated resting growth hormone levels because of the severity of their stress reaction. But their resting plasma growth hormone levels have been found to be normal. Whether this represents lack of activation of the growth hormone-releasing center or suppression of growth hormone release by elevated blood glucose,21 high plasma corticoids,25 or other unknown factors cannot be answered.
The most striking change following the intravenous infusion of glucose was, in our cases, the release of growth hornone. The cause of this increase in plasma growth hormone in response to glucose is not clear. Growth hormone secretion following glucose was greatest in the initial 48 hours of the infarction which coincides with the acute stress reaction. The failure of almost 50% of the group A patients to have any significant change in growth hormone secretion following glucose in the first 48 hours after infarction could not be correlated with any clinical or metabolic parameter. If the patterns of glucose utilization and insulin and growth hormone secretion in patients with a'cute myocardial infarctions are the result of the endocrine and metabolic alterations that occur in severe stress, they should be very similar to those that occur following surgery. Ross and co-workers26 in studying the effect of abdominal operation found that glucose tolerance was decreased and that insulin and growth hormone secretions following glucose were increased. Both the insulin and growth hormone responses to glucose were maximal during the first 24 hours after surgery and decreased toward normal by 72 hours. Glucose utilization was most impaired within the first 24 hours.
While the present data on glucose utilization and growth hormone secretion in response to glucose in the patients with acute cardiac infarction are similar to those findings following surgery, the pattern of insulin secretion in response to glucose is strikingly different. Since the degree of acute stress is probably comparable, some other factor must account for the different pattern of insulin secretion.
One major difference between surgery and a myocardial infarction is the time sequence in the repair process. In primary wound healing, fibroblastic and endothelial proliferation start within the first 24 hours, and the entire healing process is over in 10 to 14 days. 27 Studies of the anatomic changes during the evolution of a moycardial infarction have shown that capillary growth into the infarct is first noted on the third or fourth day and is maximal sometime during the third to sixth week. Fibroblasts appear at the periphery of the infarcted muscle by the fourth day and are maximal from the seventh to the twenty-first day.28 29 Thus one might expect factors involved in healing in surgery to be maximal the first 2 or 3 days while those involved in tissue regeneration in a myocardial infarction to be maximal between 6 and 18 days.
Thus the data raise the possibility that the exaggerated insulin response to glucose in group A patients in period 2 is related to the repair process. While this theory cannot be proven by the present data, it could, however, explain the different pattern of insulin secretion in the group B patients. All of those patients had myocardial damage extending back 7 to 14 days prior to the acute occlusion, and presumably the occlusion occurred while the myocardium was undergoing reparative changes from the original injury. This could account for insulin secretion being highest in period 1.
There is ample biochemical evidence to support the concept of insulin as an anabolic agent. Wool and co-workers30-32 have repeatedly demonstrated effects of insulin on protein synthesis in muscle. Gudbjarnason and associates'0 have shown that both insulin and growth hormone increase glycine-2'4C incorporation into the connective tissue of the healing infarct in experimentally produced myocardial infarctions. Singh and Udupa33 have presented evidence that insulin accelerated the process of fracture repair in experimental lesions in rats.
The findings in the present study on metabolic alterations in acute myocardial infarctions seem to indicate that the alterations in glucose utilization and growth hormone secretion occur early in the course of the illness and are either part of the acute stress response or related to other alterations caused by it. The pattern of insulin secretion is more complex, and the most striking changes occur in a later stage of illness. It is not possible to relate those changes in insulin secretion to the acute stress response, but the possibility that the exaggerated insulin response is related to the repair process, though not capable of proof by the present data, is nonetheless intriguing. More definitive studies related to this are currently underway.
AMERICAN HEART ASSOCIATION
Mitral Stenosis and Angina Pectoris
John Hunter (circa 1790)
Rheumatic Heart Disease
John Hunter before his death in 1793 had collected a whole set of specimens of rheumatic carditis. The condition was first recognized in print in 1797. Perhaps the most impressive of these is . . [depicted in] Fig. lb , which shows severe mitral stenosis with a very large left atrium. Of this Hunter writes, "The diminished size of the aperture between the auricle and the ventricle deserves particular notice." This specimen very probab'y belongs to a Miss Wood whose case history Hunter gives in detail (Hunter, Ms. c). For two years she suffered from dyspnoea and substernal pain. At autopsy, Hunter found the signs of congestive heart failure. "In the heart itself," he writes, "the left auricle was thicker in its coats than common, particularly near the ventricle. The valvulae mitrales adhered to one another all round; were become extremely thick and hard, by which means they must have lost a considerable deal of their intended use; the blood must have found a passage back to the auricle." Aortic valvular disease was also present with thickened valve cusps. Hunter tells how Dr. Heberden had been consulted, and had accepted the patient's substernal pain as a true example of angina pectoris. This must surely be the earliest instance of the recognition of angina pectoris as a symptom of mitral stenosis. Unfortunately the case is undated.-KENNETH D. KEELE: John Hunter's Contribution to Cardio-vascular Pathology. Ann Roy Coll Surg Eng 39: 248, 1966. Circulation, Volume tXXX1X, Feb7uary 1969
